Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Treatment with oral antidiabetic drugs (OADs) for at least three months before trial start at an unchanged dose~* HbA1c: 7.0-10.0%~* Body Mass Index (BMI) no higher than 40.0 kg/m\^2~* For the extension trial only: Completion of the 52 week treatment period in trial NN1250-3579 (NCT00982644)~Exclusion Criteria:~* Treatment with exenatide or liraglutide within the last 3 months before trial start~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures~* Cancer and medical history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).